9. Teaching opportunities for the day are highlighted
10. When I am the one giving handover, I feel comfortable
doing so
11. Paediatric handovers at Peterborough are enjoyable and
non-intimidating.

Percentage of staff that gave an agree/strongly agree
response to each survey statement (table 1).

**Conclusion** The intervention improved the quality of our
morning handover sessions. A follow up survey is being put
in place to assess whether these improvements have been
sustained.

### Abstract 103(P) Table 1 Percentage of staff that gave an agree/strongly agree
response to each survey statement

<table>
<thead>
<tr>
<th></th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
<th>8</th>
<th>9</th>
<th>10</th>
<th>11</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pre</td>
<td>66.67%</td>
<td>86.67%</td>
<td>93.33%</td>
<td>80%</td>
<td>60%</td>
<td>40%</td>
<td>80%</td>
<td>66.67%</td>
<td>60%</td>
<td>73.33%</td>
<td>86.67%</td>
</tr>
<tr>
<td>Post</td>
<td>80%</td>
<td>90%</td>
<td>60%</td>
<td>100%</td>
<td>80%</td>
<td>50%</td>
<td>90%</td>
<td>100%</td>
<td>90%</td>
<td>80%</td>
<td>80%</td>
</tr>
</tbody>
</table>

**Results** 416 CYP on immunosuppression identified; data were
collected on 77 (18.5%), with cross-speciality representation.
47/77 children are currently prescribed ≥2 agents with 8/77
presently off immunosuppression. 46/77 were not pre-
scribed prophylaxis at any point. In those who were, cotri-
moxazole (n=28) was commonest.
54/77 patients had past VZV exposure documented or
tested. 77/77 patients attended after chickenpox exposure; 2
required admission for treatment. 10/77 patients were hospi-
talised for possible bacterial infection; none had proven bac-
teremia but 2 developed cryptosporidiosis.
All patients had FBC checked with varying frequency
(weekly–once only). 14/77 developed lymphopaenia; of these,
8 had subsets checked. There was no clear relationship
between specialty and monitoring frequency.
Two specialities were able to provide departmental guidance
for the management of intercurrent infection.

**Conclusions** There is a large population of CYP on a wide
range of immunosuppression. There is inter-speciality variation
in the agents prescribed, monitoring schedules, infection risk
stratification and antimicrobial prophylaxis. Departmental pro-
tocols are uncommon and not readily accessible outside of
speciality or hospital, making out-of-hours decisions unnecessa-
arily challenging.
This wide variation in practice and lack of evidence-based
guidance is unacceptable.
Regional immunosuppression guidance may improve the
quality of care offered to immunosuppressed children in our
region.

### G105(P) INITIATIVE TO IMPROVE CLINICAL CODING FOR
PATIENT ADMISSION EPISODE (INPATIENT) BY
RECORDING PATIENT CO-MORBIDITIES

1M Joshi, 2S Bandi, 3R Ball. 1Department of Paediatrics, Leicester Royal Infirmary, University Hospitals of Leicester NHS Trust, Leicester, UK; 2Transformation Lead, Women’s and Children’s CMG, Management, University Hospitals of Leicester NHS Trust, Leicester, UK

10.1136/archdischild-2020-rcpch.83

**Background** We reviewed benchmarking data about comorbid-
ities in paediatric medicine provided by Civil Eye Research
compared to other tertiary hospital. The data showed that our
hospital (paediatric medicine) was on the lowest spectrum
compared to other hospitals of similar size. This prompted us
to look it in depth with an aim to improve our recording of
co-morbidities and clinical coding.

**Aim** To record patient co-morbidities during each admission
episode.

**Methods** We applied Quality Improvement (QI) methodology
(PDSA cycle- Plan, Do, Study, Act) in this project.
Coding champion’s role helped to bridge the gap between
clinical coding and the medical teams. We identified relevant
c-o-morbidities and designed a paediatric co-morbidity sheet.
These sheets were formally launched on all the paediatric

---

**Aims** Immunosuppression has become integral to the manage-
ment of a wide range of childhood illness. Although total
numbers of children and young people (CYP) on immu-
unosuppression is unknown, they are thought to be increasing.
Multiple paediatric sub-specialities initiate and monitor differ-
ent immunosuppressive therapies with anecdotal variation in
prescribing and monitoring practices. To understand existing
variations in care, we undertook a retrospective review,
focussing on:
- Number of CYP on immunosuppression;
- Drug monitoring and antimicrobial prophylaxis;
- Numbers of serious infections.

**Methods** CYP attending our hospital on immunosuppressive
medication were identified from specialty teams (excluding
immunology/oncology patients). Immunosuppressive agents
were defined as:
- Long-term/high-dose steroids
- Cytotoxic drugs
- Biologic agents/monoclonal antibodies

Data were collected on a representative sample of patients
under each specialty:
- Diagnosis;
- Current/past immunosuppression;
- Current/past antimicrobial prophylaxis;
- Consideration of risk for specific infections;
- Serious infective episodes.

Existing specialty/departmental guidance on prescribing,
monitoring and surveillance was collected.

---

**Aim** The intervention improved the quality of our
morning handover sessions. A follow up survey is being put
in place to assess whether these improvements have been
sustained.

### G104(P) CRIT: CHILDREN RECEIVING IMMUNOSUPPRESSIVE
THERAPY: A CROSS-SPECIALITY REVIEW OF PRACTICE
AT A TERTIARY CHILDREN’S HOSPITAL

1C Tuillif, 2A Batterby, 2E Williams, 2F Flood, 2A Flinn, 2F McErlane, 2S Sampath. 1General Paediatrics, Great North Children’s Hospital, Newcastle upon Tyne, UK; 2Department of Paediatric Immunology, Great North Children’s Hospital, Newcastle upon Tyne, UK; 3Department of Paediatric Rheumatology, Great North Children’s Hospital, Newcastle upon Tyne, UK

10.1136/archdischild-2020-rcpch.82
wards and medical & nursing staff was updated via regular teaching and educational sessions.

We completed one audit cycle by retrospectively reviewing 20 patient medical notes each time (May-June 2019 & August-September 2019).

**Results** Our first audit showed that only 20% (4/20) patient notes had a co-morbidity sheet whereas the re audit post educational sessions helped to improve it to 75% (15/20).

Since implementing the co-morbidity sheet and using it regularly from April 2019, our low bracket coding (between 0–1 co morbidity) reduced from 40% to 27%; mid bracket coding (2–5 comorbidities) improved from 47% to 54% and the highest bracket coding(6+ co morbidities) improved from 13% to 19%. Overall this resulted in a financial gain of £195,000 since the implementation of co-morbidity sheet.

**Conclusion** Comorbidities are conditions that are present in association with a current illness with which a patient is admitted. It is very important to document comorbidities in clinical notes and discharge summaries which can then be coded accurately. This in turn helps to secure appropriate funding to provide appropriate and effective patient care. Our experience shows that using a co-morbidity sheet based on common health conditions helps clinical as well as coding staff to improve clinical coding. Regular updates via educational sessions about the benchmarking data and PDSA cycles are key to sustain this improvement.

---

### Abstract Withdrawn

---

### Reducing Paracetamol Medication Errors in Children

**1. Cook, 2Y Horke, 3R Cooper. 1Pharmacy, Chelsea and Westminster FT, London, UK; 2Paediatric Department, Chelsea and Westminster FT, London, UK**

**10.1136/archdischild-2020-rcpch.84**

**Introduction** Paracetamol is one of the most common medicines administered to children nationally. Accidental overdoses with intravenous (IV) paracetamol in children <10 kg have been reported, including fatalities. High numbers of medication incidents (MI) involving prescribing and administration of paracetamol on paediatric inpatient wards were reported. To reduce the level of harm the multidisciplinary team reviewed incident trends and implemented selected interventions.

**Method** MI were recorded and reviewed retrospectively every quarter (Q) from Q1 March-May 2018 to Q2 July-Sept 2019. Ethics approval was not required for this study. Selected measures were then used to track changes in incident numbers and trends on implementation of intervention.

**Measures**

- Number of paracetamol incidents
- Level of harm
- Incident type – categorised into trends.

**Intervention 1** (Q3 October-December 2018) Paracetamol medication safety bulletin, highlighting risks associated prescribing paracetamol in children was circulated to staff. Standardised dosing approved in cross-site guideline. Targeted staff education around incident data, trends and top tips. Removal of multi-route screens on the electronic prescribing system to reduce number of IV paracetamol prescriptions.

**Intervention 2** (Q1 March-May 2019) Introduction of dose/volume checks for intravenous paracetamol included in the paediatric IV guide.

**Results**

- 75% reduction in number of paracetamol errors. A 65% reduction in the total percentage MI involving paracetamol.
- 50% reduction in number of MI with a reported level of harm, the level of harm remained the same
- 100% reduction of oral dosing errors. 50% reduction in number of IV dosing errors for babies <10 kg and 40% reduction in duplication of doses.

**Conclusion** No reported IV paracetamol dosing errors for babies <10 kg in Q1-2 2019.

---

### Implementation of a Prolonged Jaundice Pathway: A Quality Improvement Initiative. Time for NICe to Have a Rethink!

**SK Kumar, PS Surana. Neonatal Unit, University Hospitals Birmingham NHS Trust, Birmingham, UK**

**10.1136/archdischild-2020-rcpch.85**

**Introduction** Prolonged neonatal jaundice (PNJ) is mostly benign and self-limiting; however, it could represent a serious pathology such as biliary atresia; timely identification of which is vital. NICe guidance is available on PNJ, however, hospital referrals of all such infants can lead to over-investigation, unnecessary pressure on hospital resources and undue parental anxiety. Hence, there needs to be a fine balance between over-investigating well infants and timely detection of serious pathology.

**Background** Previously, all cases of community diagnosed PNJ were referred to consultant clinic in our tertiary neonatal unit. An audit in 2013(Jan-Dec) revealed a high number (222) of such referrals. Of these, 38% were not even clinically jaundiced at the time of clinic attendance. The rest had unnecessary investigations-91% and 61% had liver and thyroid function tests respectively; not recommended by NICe.

**Aim** The above audit prompted a quality improvement initiative of implementing an alternative pathway to streamline PNJ referrals in Sep’15. As per the pathway, community midwives perform direct and indirect bilirubin on infants and refer only if any of the following criteria are met; not thriving, pale stools, total bilirubin>200 ummol/L, direct bilirubin>20 ummol/L or worsening jaundice despite blood test.

**Method** A re-audit was performed in May’19 to evaluate the efficacy of the pathway over 3 years(Mar’16-Feb’19) and to assess any delay in diagnosing serious pathology.

**Results** Table 1 compares results before and after implementation of PNJ pathway.